When it comes to health care, ObamaCare or all things in between Republicans and Democrats in Congress cannot agree on anything. That is until now. It appears that the leadership in both the Senate and the House and from both parties are committed to gaining some control over the price of pharmaceuticals.
The concept agreed upon is one to bring down some of the walls that keep out competition. One of today’s practices is to pay competitors from entering the market with a generic drug. Another is to tweak a drug in a small way to extend the life of the patent.
Kentucky Sen. Rand Paul — a Republican — said the federal government controls Medicare and Medicaid and he and many of his colleagues think it ought to use its power as the major purchaser of many drugs to do away with those practices.
“There is a possibility we could get to bipartisan agreement on some of this stuff, particularly if they’re getting government money, I think there could be some more rules on people that are consuming a lot of government money,” he said.
Those agreeing with Paul want price transparency. This would show the public and officials how prices are set and how pharmacy benefit managers negotiate for discounts and whether the dollars for those discounts are actually passed onto consumers.
On the other side of the Capital building is the House and House Energy and Oregon Republican and Commerce Committee Chairman Rep. Greg Walden said he’s planning on holding a public hearing next year on drug prices.
Source link: Insurance Business America